Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07684170 |
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms |
NOT_YET_RECRUITING | PHASE2 |
| NCT07662031 |
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07419841 |
A Phase 1 Study of the Safety and Tolerability of CTX-10726 |
RECRUITING | PHASE1 |
| NCT07392957 |
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06150664 |
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies |
RECRUITING | PHASE1 |
| NCT05513742 |
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer |
COMPLETED | PHASE2 |
